Possible Interaction: Quercetin and Ng-Nitroarginine Methyl Ester

“Also, L-NAME (100 μM), a non-selective NO synthase (NOS) inhibitor, blocked the effects of quercetin on pacemaker activity and quercetin stimulated cGMP production.”

“Thus, quercetin administration counteracts l-NAME effects on NO bioavailability determinants in vivo, essentially through controlling NOX-mediated superoxide anion production.”

“ L-NAME , indomethacin, and ODQ treatment also decreased the potency of quercetin.”

“Administration of L-NAME prior to administration of quercetin and rutin, significantly reduced the cerebroprotection offered by quercetin and rutin.”

“The vasorelaxant effect of quercetin was partially but not significantly (p > 0.05) inhibited by L-NAME (100 μM) or indomethacin (10 μM), suggesting that the vasorelaxant effect of the flavonoid was unlikely to be mediated via endothelium-dependent relaxing factor (EDRF), or through prostacyclin (PGI2) pathways.”

“ Nw‐nitro‐L‐arginine methyl ester (l‐NAME, 10 mmol/L) significantly attenuated the vasodepressor effects of quercetin and ascorbic acid, raising the responses to PE to a level similar to that observed in the control SHR tissues.”

“Furthermore, both nitro-L-arginine-methyl ester (L-NAME, 100 microM) and indomethacin (10 microM) markedly attenuated the vasorelaxant responses following quercetin application.”

“The antiperistaltic effect of quercetin was partially prevented by apamin (0.5 µmol/l), N-nitro-L-arginine methylester (100 µmol/l) and naloxone (0.5 µmol/l), whereas the effect of genistein was hardly affected by these drugs.”

“ Quercetin produced a similar relaxation, which was also abolished by L-NAME.”

“Inhibiting mitoKATPchannels by 100 μM 5-hydroxydecanoate and blocking NO system by 100 μM L-NAME reversed the cardioprotective effects of Que.”